Related Experiment Video
Updated: Jun 16, 2026

Microscopy-based Assays for High-throughput Screening of Host Factors Involved in Brucella Infection of Hela Cells
Published on: August 5, 2016
A Brucella melitensis H38ΔwbkF rough mutant protects against Brucella ovis in rams
Pilar M Muñoz1,2, Raquel Conde-Álvarez3, Sara Andrés-Barranco4,5
1Departamento de Ciencia Animal, Centro de Investigación y Tecnología Agroalimentaria de Aragón (CITA), Zaragoza, Spain. pmmunnoz@cita-aragon.es.
Abstract:
Brucella melitensis and Brucella ovis are gram-negative pathogens of sheep that cause severe economic losses and, although B. ovis is non-zoonotic, B. melitensis is the main cause of human brucellosis. B. melitensis carries a smooth (S) lipopolysaccharide (LPS) with an N-formyl-perosamine O-polysaccharide (O-PS) that is absent in the rough LPS of B. ovis. Their control and eradication require vaccination, but B. melitensis Rev 1, the only vaccine available, triggers anti-O-PS antibodies that interfere in the S-brucellae serodiagnosis. Since eradication and serological surveillance of the zoonotic species are priorities, Rev 1 is banned once B. melitensis is eradicated or where it never existed, hampering B. ovis control and eradication. To develop a B. ovis specific vaccine, we investigated three Brucella live vaccine candidates lacking N-formyl-perosamine O-PS: Bov::CAΔwadB (CO2-independent B. ovis with truncated LPS core oligosaccharide); Rev1::wbdRΔwbkC (carrying N-acetylated O-PS); and H38ΔwbkF (B. melitensis rough mutant with intact LPS core). After confirming their attenuation and protection against B. ovis in mice, were tested in rams for efficacy. H38ΔwbkF yielded similar protection to Rev 1 against B. ovis but Bov::CAΔwadB and Rev1::wbdRΔwbkC conferred no or poor protection, respectively. All H38ΔwbkF vaccinated rams developed a protracted antibody response in ELISA and immunoprecipitation B. ovis diagnostic tests. In contrast, all remained negative in Rose Bengal and complement fixation tests used routinely for B. melitensis diagnosis, though some became positive in S-LPS ELISA owing to LPS core epitope reactivity. Thus, H38ΔwbkF is an interesting candidate for the immunoprophylaxis of B. ovis in B. melitensis-free areas.
Insights
Developing a new vaccine for Brucella ovis is crucial for sheep farming. The H38ΔwbkF vaccine candidate shows promise, offering protection against B. ovis without interfering with Brucella melitensis diagnosis.
Area of Science:
- Veterinary Microbiology
- Immunology
- Animal Health
Background:
- Brucella melitensis and Brucella ovis cause significant economic losses in sheep.
- Current B. melitensis Rev 1 vaccine interferes with serological diagnosis of B. melitensis.
- Need for a B. ovis-specific vaccine that does not cross-react with B. melitensis.
Purpose of the Study:
- To develop and evaluate novel live vaccine candidates for Brucella ovis.
- To identify a vaccine that elicits protection against B. ovis without cross-reactivity in B. melitensis diagnostic tests.
Main Methods:
- Investigated three Brucella live vaccine candidates lacking N-formyl-perosamine O-polysaccharide.
- Assessed attenuation and protection against B. ovis in mice and rams.
- Evaluated antibody responses using ELISA, immunoprecipitation, Rose Bengal, and complement fixation tests.
Main Results:
- H38ΔwbkF demonstrated protection against B. ovis comparable to Rev 1 in rams.
- Bov::CAΔwadB and Rev1::wbdRΔwbkC provided poor or no protection.
- H38ΔwbkF induced B. ovis-specific antibodies but did not interfere with routine B. melitensis serological tests.
Conclusions:
- H38ΔwbkF is a promising candidate for B. ovis immunoprophylaxis in B. melitensis-free regions.
- This vaccine avoids serological interference, facilitating simultaneous eradication and surveillance programs.

